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ABSTRACT 
Vitamin D deficiency is evident in many parts of the world, even in the sunnier regions, for a variety of reasons. Recently, vitamin D has been 
reported in many scientific researchers as an important factor that may have significant health benefits in the prevention and the treatment of many 
chronic illnesses such as depression. According to the Global Burden of Disease Study, depression is one of the world's leading causes of disability 
and affects 350 million people in all communities across the world. Depressive disorders often start at an early age; they reduce people’s 
functioning, and they are the leading cause of disability worldwide in terms of total years lost due to disability. The demand for curbing and 
preventing depression is on the rise globally. The present review will highlight the relation between vitamin D deficiency and the risk of depression 
among the different population. It will also discuss the epidemiology of vitamin D supplementation and depression from a variety of sources both 
suggesting and disproving their relation.  
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The generic term vitamin D designates a group of chemically related 
compounds; the two most prominent members of this group are 
vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol) [1]. They 
are structurally similar secosteroid derived from the UV irradiation 
of provitamin D sterols. In vertebrates, vitamin D3 is produced in 
vivo by the action of sunlight on 7-dehydrocholesterol in the skin [2]. 
Since both forms of this vitamin are metabolized to a biologically 
active form that functions as a steroid hormone and the body is 
capable of producing vitamin D3, vitamin D does not meet the 
classical definition of a vitamin. A more accurate description of 
vitamin D is that it is a prohormone [3]. However, since vitamin D 
was first recognized as an essential nutrient, it has historically been 
classified among the lipid-soluble vitamins [3]. 
Sources and food fortification 
Most natural foods have a low content of vitamin D3. Fish liver oil is 
an exceptional source of vitamin D2. The D-provitamins, ergosterol, 
and 7-dehydrocholesterol are widely distributed in the animal and 
plant kingdoms. Yeast, some mushrooms, cabbage, spinach and 
wheat germ oil are particularly abundant in provitamin D2. Vitamin 
D3 and its provitamin are present in egg yolk, butter, cow’s milk, beef 
and pork liver, mollusks, animal fat and pork skin [4]. However, in 
individuals with ample sunlight exposure the greater source is 
endogenous vitamin D [5]. 
In many countries, the predominant dietary sources of vitamin D are 
fortified foods, such as milk, yogurt, orange juice, breakfast cereals, 
and dietary supplements. Vitamin D2 is manufactured through the 
ultraviolet irradiation of ergosterol from yeast, and vitamin D3 through 
the ultraviolet irradiation of 7-dehydrocholesterol from lanolin [5]. 
Absorption, metabolism, and excretion 
Because dietary vitamin D is fat soluble, once it is ingested in the 
small intestine, it is incorporated into the chylomicron fraction and 
absorbed through the lymphatic system [6]. Once vitamin D enters 
the circulation from the skin or from the lymph, it accumulates in 
the liver within a few hours. Vitamin D is readily metabolized in the 
liver to 25-hydroxyvitamin D3 which is the most abundant form of 
vitamin D in circulation [7]. Further metabolism of 25-
hydroxyvitamin D3 to the active metabolite 1,25-dihydroxyvitamin 
D3 occurs in the kidneys (fig. 1) [7]. 
  
 
Fig. 1: Major metabolic pathway of vitamin D 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 8, Issue 1, 2016 
Zam 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 16-22 
 
17 
The production of 1, 25-dihydroxyvitamin D3 in the kidney is tightly 
regulated, principally through the action of PTH in response to 
serum calcium and phosphorus levels (fig. 2) [8]. 
 
 
Fig. 2: Regulation of the production of 1, 25-dihydroxyvitamin 
D3 in the kidney, Adapted from reference Dusso AS 
and Tokumoto M [9]. doi: 10.1038/ki.2010.543 
 
Although 1,25-dihydroxyvitamin D3is the biologically active form of 
vitamin D, it is not the ideal measure for vitamin D status since its 
half-life is only 4-6 h, and the circulating levels of 1,25-
dihydroxyvitamin D3are thousand fold less than 25-hydroxyvitamin 
D3 [8]. 25-hydroxyvitamin D3is the major circulating forms of 
vitamin D that has a half-life of approximately 2-3 w [10, 11].  
Groups at risk for vitamin d deficiency 
Optimal vitamin D status is hampered by several factors. The limited 
number of naturally rich foods with this nutrient causes some 
groups to be at risk for inadequacy. The current Adequate Intake 
(AI) is 200 IU/day for both women and men from infancy to age 50; 
400 IU/day for those between 51–70 y; and 600 IU/day for 
those>70 y [12]. Recently, the American Academy of Pediatrics 
recommended increasing the daily intake of vitamin D to 400 IU/day 
for all infants, children, and adolescents [13]. 
Vitamin D deficiency is now a global public health problem affecting 
a billion people worldwide. It is defined by most experts as a 25-
hydroxyvitamin D level of less than 20 ng per milliliter (50 n mol/ 
liter) [14]. Levels ranged between 21 to 29 ng per milliliter (52 to 72 
n mol/liter) can be considered to indicate a relative insufficiency of 
vitamin D [15], and a level of 30 ng per milliliter or greater can be 
considered to indicate sufficient vitamin D [16]. 
Vitamin D deficiency can arise from lack of sunlight exposure, lack of 
dietary vitamin D intake, or impaired intestinal absorption of the 
vitamin. 
Intestinal disorders 
Impairment of intestinal absorption of vitamin D can occur in 
intestinal disorders that result in the malabsorption of fat such as 
tropical sprue, regional enteritis, and multiple jejunal diverticulosis 
[17]. Surgical conditions, such as gastric resection and jejunal–ileal 
bypass surgery for obesity, may also impair vitamin D absorption.  
Liver disorders 
The liver is the source of the bile salts that aid in the intestinal 
absorption of vitamin D. Hence, malfunctions of the liver can 
interfere with the absorption, transport, and metabolism of vitamin 
D. Vitamin D deficiency have been reported in patients suffering 
from either primary biliary cirrhosis or from the prolonged 
obstructive jaundice [18]. 
Renal disorders 
Patients with renal failure often also suffer from vitamin D 
deficiency. Studies on the metabolism of radioactively labeled 
vitamin D in normal persons versus patients with chronic renal 
failure have proved that the circulating level of 1α, 25 (OH)2 D3 in 
normal subject was in the range of 30–35 pg/ml, whereas in chronic 
renal failure the levels have been reported as low as 3–6 pg/ml [19]. 
A successful renal transplant results in the return of 1α, 25(OH)2 D3 
levels to the normal range [20]. 
Parathyroid disorders 
Hypoparathyroidism results in a slight reduction in circulating 1α, 
25(OH)2 D3 levels has been reported [21].  
Age 
Further, 1α, 25(OH)2 D3 levels in the plasma and responsivity of the 
renal 25(OH)D3-1α-hydroxylase to PTH are both known to decrease 
with age [22]. 
Sex differences 
Findings from the National Health and Nutrition Examination Survey 
(NHANES-III, 2001-2004), which included more than 15,000 adults, 
indicated significantly lower levels of vitamin D for female than male 
participants [23].  
Race 
For individuals who have darker skin, decreased vitamin D is more 
common. Due to higher melanin levels, dark-skinned individuals 
experience reduced subcutaneous vitamin D synthesis compared to 
those with lighter pigmentation, making them another high-risk 
group for vitamin D deficiency [24]. 
Body weight 
Obesity has been found to be inversely related to vitamin D level 
[25]. This may be due to excess adipose tissue that sequesters 
vitamin D thereby altering its release into circulation [25]. Body 
image concerns may also cause obese individuals to avoid skin 
exposure to the sun resulting in inadequate vitamin D levels [26].  
Depression disorder  
Description 
Depression, in its own right, is a disabling condition impairing all 
aspects of human function and impacts society by increasing suicide 
risk. In persons with a chronic medical disease, depression often 
makes the management of chronic illness more difficult. The 
Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV) [27] provides a general definition for mental 
disorder: “a clinically significant behavioral or psychological 
syndrome or pattern that occurs in an individual and that is 
associated with present distress or disability or with a significantly 
increased risk of suffering death, pain, disability, or an important 
loss of freedom.”Depression should not be mistaken for simple 
feelings of unhappiness or grief. 
Untreated depression can last for six months or more. In a 
prospective psychiatric epidemiological survey, the mean time to 
recovery was 8.4 mo and nearly 20% had not recovered at 24 mo 
[28]. A majority of patients improve significantly with 
antidepressants treatment [29]; however, depression often has a 
recurrent course, with multiple episodes of relapse [30] 
Prevalence 
Currently, the WHO has determined that depression is ranked fourth 
on the global burden of disease list. The rates of depression continue 
to increase, and the WHO predicts that it will be the second most 
common global burden of disease after cardiovascular disease by the 
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year 2020 [31]. Lifetime prevalence levels from community-based 
surveys range from 4.9% to 17.1% [32].  
Longitudinal studies suggest that about 80% of individuals 
experiencing a major depressive episode will have at least one more 
episode during their lifetime, and approximately 12% of patients who 
suffer from depression will have a chronic, unremitting course [33]. 
General causes 
Unlike other illnesses or disorders, there is no simple explanation as 
to what causes depression. The general scientific understanding is 
that depression does not have a single cause; it arises from multiple 
factors that may need to occur simultaneously. A person’s life 
experience, stress, genetic inheritance, age, sex, brain chemistry 
imbalance, hormone changes, substance use and other illnesses all 
play significant roles in the development of depression. 
Gender 
In fact, the burden of depression is 50% higher for females than 
males in low-and-middle-income countries as well as in high-income 
countries [34]. Research in developing countries suggests that 
maternal depression may be a risk factor for poor growth in young 
children [35]. This risk factor could mean that effects of depression 
affect not only this generation but also the next. 
Genetic factors 
The occurrence of mood disorders and suicides tend to run in families. 
Among the first-degree relatives of patients with major depression, the 
prevalence of major depression is some two to three times higher than 
among the first-degree relatives of normal controls. Furthermore, the 
genetic risk of developing clinical depression is 30% in the case of 
complete genetic inheritance such as identical twins, which means 
only about 30% of the time when one twin develops depression, will 
the other twin. These results indicate that depression is unlikely to 
occur without stressful life events [36]. 
Despite these findings, however, genetic studies have not as yet 
identified any genes which can be confidently associated with this 
illness, indicating that in all likelihood major depression is 
genetically complex, involving not only multiple genes but also 
possibly multiple modes of inheritance [37]. 
An interesting genetic vulnerability factor is allelic variation in the 
promoter region of the gene encoding the serotonin 5-HT 
transporter (5HTT) [38].  
Age 
MDD (Major Depressive Disorder) can present at any age, but the 
peak prevalence occurs in those between the ages of 15 and 45 y 
[39]. Generally, the depressive episodes occurring in the mid-
twenties are associated with a biologically inherited tendency to 
develop depression, whereas those occurring after age 60 are less 
likely to be due to a genetic predisposition [39]. 
Stress 
One of the cardinal features of depression is its recurrent nature. Some 
patients experience regular or periodic recurrence, whereas in other 
patients recurrence is aperiodic. Certain biological (e. g., short allele of 
serotonin transporter gene promoter region polymorphism, the release 
of hormones from the adrenal gland as part of the organism’s general 
stress response) and psychological (e. g., neuroticism, cognitive 
vulnerability) markers have been identified as possible risk factors for 
recurrence of depression in the context of stress [38, 40, 41]. 
However, the effect of the short allele of the 5HTT has been criticized as 
implausible because of the small effect size of polymorphic variation on 
the phenotypic expression of complex traits [36]. In addition, carriers of 
the short allele of the 5HTT do not seem much more likely than carriers 
of the long allele to experience depressive illness, which would be 
expected if they were more susceptible to stress [42]. 
Physical illness and substances use 
Depression is an expected consequence of any chronic illness; these 
may include disorder of the CNS, systemic disorders such as 
cardiovascular disease and cancer. Studies found that about 10-18% 
of depressive disorders can be triggered by an existing medical 
condition. 
Major depression affects approximately 25% of people recovering 
from a myocardial infarction, and another 40% suffer from mild 
depression. Patients identified with depression were twice as likely 
to experience recurrent cardiovascular events and were less likely to 
follow dietary, exercise, and medication recommendations [42]. 
Depression can be seen in up to one-half of all stroke patients. 
Psychotherapy has been associated with modest improvement in 
post-stroke depression and is considered to be part of a 
multidisciplinary approach [43, 44]. 
Depression has also been seen in association with diabetes and severe 
obesity, particularly in younger patients and in women [45, 46]. 
It is estimated that 25% of children with Attention-deficit/ 
hyperactivity disorder (ADHD) have a comorbid anxiety disorder, 
and approximately these children have comorbid major depressive 
disorder [47]. 
Chronic cannabis use is associated with various psychiatric 
disorders, most commonly anxiety disorders and depressive 
disorders [48]. One of the common adverse reactions of melatonin 
includes transient depressive symptoms [49]. 
Biochemical factors 
It is likely that with most instances of clinical depression, 
neurotransmitter function is disrupted especially serotonin, 
noradrenaline and dopamine [41]. 
Depression medical treatment strategies 
The treatment of MDD can be divided into two phases: acute and 
maintenance. The aim of acute treatment is to eliminate symptoms 
of depression and restore psychosocial functioning. The aim of 
maintenance treatment is to ensure a return to baseline function 
and quality of life and to prevent recurrence of symptoms. 
First-line medications are the selective serotonin reuptake inhibitors 
(SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs), and 
newer agents because they have better safety and tolerability profiles 
than older medications like tricyclic antidepressants (TCAs) and 
monoamine oxidase (MAO) inhibitors [50]. TCAs are recommended as 
second-line antidepressants, whereas MAO inhibitors are 
recommended as third-line because of tolerability and safety issues 
and dietary and drug restrictions.  
Light therapy of depression 
Light therapy consists of daily exposure to bright light; it includes 
wavelengths between 280-320 nm which allow the skin to produce 
vitamin D [51]. The previous Canadian guidelines noted the 
considerable RCT evidence for light therapy in the acute treatment 
of seasonal MDD [50]. Although, few studies compared light therapy 
to antidepressants; one RCT found comparable effectiveness 
between a standard course of light therapy and fluoxetine 20 mg 
[52]. Several systematic reviews of light therapy for nonseasonal 
MDD have reported the efficacy of bright light against placebo 
conditions [51, 53]. The side effects of bright light therapy include a 
headache, eye strain, nausea, and agitation, but these are generally 
mild and rarely lead to treatment discontinuation.  
The combination between light therapy and exercise is also well-
known alternative treatments to depression. This can easily be 
accomplished by encouraging people to exercise outdoors during 
daylight hours. However, the benefit of exercise with natural 
sunlight exposure needs to be weighed against the risk of skin 
cancer if sun exposure is significant. Therefore, additional research 
is needed in this area [54]. 
Epidemiologic studies of the relationship between vitamin d 
and depression 
Partonen et al. [55] studied the effect of exposure to the sun for one 
hour or 15 min in the morning for two weeks in the winter. The 
study was performed on 29 patients (16 with seasonal affective 
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disorder (SAD) and 13 controls). One hour of light therapy 
significantly decreased depressive symptoms more so in the group 
with SAD than the control group (p= 0.003). In another study, a 
group of 80 participants aged between 60 to 92 y, 40 with mild 
Alzheimer disease (AD) and 40 non demented persons, were 
selected. 58% were noted to have vitamin D insufficiency. In 
addition, this insufficiency was associated with low mood and with 
impairment on two of four measures of cognitive performance [56]. 
A recent study enrolled 2835 Korean participants aged 65 y or older. 
The serum 25-hydroxyvitamin D [25(OH)D] concentrations and 
depressive symptoms were established. Results indicated that lower 
25(OH)D concentrations were independently associated with 
depressive symptoms [57]. 
Jorde et al. [58] reported that for persons with secondary 
hyperparathyroidism (n = 21), lower serum vitamin D was 
significantly related to higher scores on the Beck Depression 
Inventory when compared to controls (n = 63, p<.05). Armstrong et 
al.[59] reported that for persons with the chronic illness of 
fibromyalgia (n = 75), 69% were noted to have deficient or 
insufficient levels of vitamin D. Depression was higher (assessed 
with the Hospital and Anxiety Depression Scale [HADS] Median = 
31) for those individuals with vitamin D deficiency when compared 
to those with insufficient (HADS = 22.5) or normal (HADS = 23.5) 
levels of vitamin D. 
Several more recent studies have examined the relationship of 
vitamin D to depressive disorders. Moran et al. [60] investigated the 
association among 25 hydroxy-Vitamin D status and depression in 
73 overweight or obese premenopausal women with and without 
PCOS (n=50, n=23, respectively). Primary outcome measures were 
25(OH)D3, mood (Hospital Anxiety and Depression questionnaire), 
and inflammation (highly sensitive C-reactive protein (hsCRP)). 
Results showed that vitamin D deficiency was not significantly 
different in women with and without PCOS (46% versus 39%, 
p = 0.311), whereas it was the only significant independent predictor 
of depression (β = -0.063 ± 0.021, p = 0.005).  
Ozkayar et al. [61] conducted a cross-sectional and descriptive study 
on 117 renal transplant patients (44 female, 73 male; mean age, 
39.0±11.7 y). Patients were stratified to two groups according to the 
cut-off point (7) of depression subscale (D) of Hospital 
Anxiety Depression Scale (HADS), with or without depression risk. 
In the group with depression risk, 25(OH) D3 levels were 
significantly lower than the other group (15.2±9.2 μg/l and 
21.9±12.7 μg/l, respectively; p = 0.004).  
In a pregnancy cohort study performed on 498 women, Huang et al. 
examined the association between serum 25(OH)D3concentrations 
and depression in early pregnancy (mean=15.4 w gestation). 
Symptoms were measured using Depression, Anxiety, and Stress 
Scales (DASS-21) and Patient Health Questionnaire 
Depression Module (PHQ-9) instruments. Mean 25 (OH) D3 
concentration was 34.4 ng/ml and approximately 12% had 
depression symptoms. A 1 ng/ml lower 25(OH)D3was associated 
with 0.043 and 0.040 higher DASS-21 Anxiety and PHQ-9 Scores (p-
values=0.052 and 0.029, respectively). Participants in the lowest 
quartile of 25(OH) D3 (<28.9 ng/ml) had 1.11 higher PHQ-9 scores 
than those in the highest quartile (≥ 39.5 ng /ml, p<0.05). However, 
associations were attenuated and statistically insignificant in fully 
adjusted models [62].  
Postpartum depression is a common disorder that affects 10-15% of 
postpartum women, and it can have negative effects on both the 
mother and newborn. Recent studies have suggested that low levels 
of vitamin D are associated with poor mood and depression. 179 
pregnant women were screened for vitamin D levels during mid-
pregnancy and in the 6th month postpartum. 11% of women had 
severe vitamin D deficiency, and 40.3% had mild vitamin D 
deficiency. The frequency of PPD was 21.6% at the 1st week, 23.2% 
at 6th week, and 23.7% at the 6th month. There was a significant 
relationship between low 25(OH)D3levels in mid-pregnancy and 
high Edinburgh Postnatal Depression Scale scores (EPDS), which is 
indicative of PPD for all three follow-up periods (p=0.003, p=0.004 
and p<0.001, respectively) [63]. 
Maddock et al. [64] performed a study on 7401 participants with 
common mental disorders CMDs. Behaviors were ascertained by 
questionnaire at age 45 y. CMDs were assessed using the Clinical 
Interview Schedule-Revised at 45 y and depression using Mental 
Health Inventory-5 at 50 y. Association between 25(OH)D and 
subsequent (50 y) risk of depression were non-linear (p = 0.01), 
with lower risk for participants with 25(OH)D between 50 and 85 n 
mol/l compared with those with lower or higher concentrations. In 
another cross-sectional study, the cognitive performance and serum 
25(OH)D levels were explored in 254 older (>60 y) as well as 
younger (30-60 y) adults. Results showed that a low vitamin D level 
was associated with greater risk of cognitive impairment in older as 
well as younger adults [65]. 
Epidemiologic studies of the effect of vitamin d 
supplementation on depressive disorders 
Although vitamin D deficiency has been associated 
with depressive symptoms, the role of vitamin D supplementation in 
the management of depression is still controversial. Some results of 
randomized controlled trials (RCTs) investigating the efficacy 
of vitamin D in depression suggest a positive association; while 
others show an unconvincing association. 
Jorde et al. [66] performed a 1 y study comparing high doses of 
25(OH) D3 with placebo in 441 overweight and obese subjects with 
weight loss as the primary end-point. Participants were randomized 
into one of three groups where vitamin D (20,000 IU cholecalciferol) 
was given twice per week, once per week, or not at all (placebo) for 
one year. All participants also received calcium supplementation 
(500 mg daily). Subjects with serum 25(OH)D3 levels<40 n mol/l 
scored significantly higher more depressive traits than those with 
serum 25(OH)D3 levels ≥ 40 n mol/l on the Beck Depression 
Inventory total (BDI) [6.0 (0-23) versus 4.5 (0-28) (median and 
range)] and the BDI subscale 1-13 [2.0 (0-15) versus 1.0 (0-29.5)] 
(P<0.05). In the two groups given vitamin D, but not in the placebo 
group, there was a significant improvement in BDI scores after 1 y. 
Limitations of the study were that only overweight and obese adults 
were included, and only a single measure of depression was used, 
while it is more effective to use more subtle measures like 
Montgomery Asberg Depression Rating Scale and HADS which could 
have yielded additional information.  
In a more recent study conducted by Kjærgaard et al. [67], 
participants with low 25(OH) D3 levels were randomized to either 
placebo or 40 000 IU vitamin D3 per week for 6 mo. Individuals with 
high serum 25(OH) D3 levels were used as nested controls. 
Depressive symptoms were evaluated with the BDI, Hospital Anxiety 
and Depression Scale, Seasonal Pattern Assessment Scale and 
Montgomery-Asberg Depression Rating Scale. Participants with low 
25 (OH)D3 levels (n=230) at baseline were more depressed (P<0.05) 
than participants with high 25(OH)D3 levels (n=114). In the 
intervention study, no significant effect of high-dose vitamin D was 
found on depressive symptom scores when compared with placebo. 
Vitamin D deficiency and depression frequently occur in patients 
with chronic liver diseases (CLD). Overall, 111 patients with CLD 
were included in a cross-sectional analysis. The serum 25-
hydroxyvitamin D [25(OH) D] concentrations and depressive 
symptoms were first established. Then, 77 patients with 
inadequate vitamin D concentrations received 20,000 IU vitamin 
D per week for six months. Results indicated that vitamin 
D replacement significantly improved depressive symptoms in 
women with CLD [68].  
A systemic review of more recent studies identified and extracted 
data from randomized trials that compared the effect of vitamin D 
supplementation on depressive symptoms to a control condition, 
seven trials (3191 participants) were included. Subgroup analysis 
showed that vitamin D supplementation for participants with 
clinically significant depressive symptoms had a moderate, 
statistically significant effect (2 studies: SMD,-0.60; 95% CI,-1.19 to-
0.01; p = 0.046), but a small and non-significant effect was observed 
for those without clinically significant depression (5 studies: SMD,-
0.04; 95% CI,-0.20 to 0.12; p = 0.61) [69]. 
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In contrast, a systematic review done by Li et al. concluded that 
there was insufficient evidence to support the efficacy of Vitamin D 
supplementation in depression symptoms. Six RCTs were identified 
with 1203 participants (72% females) including 71 depressed 
patients; five of the studies involved adults at risk of depression, and 
one trial used depressed patients. Results of the classical meta-
analysis showed no significant effect of Vitamin D supplementation 
on post-intervention depression scores (standardized mean 
difference =-0.14, 95% confidence interval =-0.41 to 0.13, P = 0.32; 
odds ratio = 0.93, 95% confidence interval = 0.54 to 1.59, P = 0.79). 
The quality of evidence was low. No significant differences were 
demonstrated in the subgroup or sensitivity analyses. Similar results 
were found when Bayesian meta-analyses were applied [70]. 
In another meta-analysis, vitamin D supplementation was used to 
reduce depressive symptoms. Studies involved 4923 participants 
aged ≥1 8 y who were diagnosed with depressive disorder. No 
significant reduction in depression was seen after vitamin D 
supplementation; however, most of the studies focused on 
individuals with low levels of depression and sufficient 
serum vitamin D at baseline [71].  
Probable vitamin d mechanism of action in depression 
The genomic action of 1,25 (OH)2D3 is mediated by the VDR (Vitamin 
D Receptor), which functions as a ligand-activated transcription 
factor in the cells of target tissues [72, 73]. The VDR is present in 
most tissues; especially bone, kidney and small intestine have high 
levels of receptor compared to other tissues [72, 73]. Numerous 
recent studies have identified VDR in neuronal and glial cells in the 
central nervous system [74]. Eyles et al. [75] identified VDR in 
multiple areas of the human brain, including the prefrontal cortex, 
hippocampus, cingulate gyrus, thalamus, hypothalamus, and 
substantia nigra; many of which have been implicated in the 
pathophysiology of depression. 
The enzymes necessary for the hydroxylation of 25hydroxyvitamin 
D to the active form 1,25dihydroxyvitamin D are also present in the 
hypothalamus, cerebellum, and substantia nigra [76]. Vitamin D 
modulates the hypothalamic-pituitary-adrenal axis, regulating 
adrenaline, noradrenaline, and dopamine production through VDRs 
in the adrenal cortex [77]; and protects against the depletion of 
dopamine and serotonin centrally [78]. Patrick et al. [79] proved 
that calcitriol activates the transcription of the serotonin-
synthesizing gene tryptophan hydroxylase 2 (TPH2) in the brain and 
represses the transcription of TPH1 in tissues outside the blood-
brain barrier. Therefore, vitamin D deficiency has been linked to an 
increased incidence of depression [80]. Maintaining vitamin D 
sufficiency in utero and during early life, to satisfy the vitamin D 
receptor transcriptional activity in the brain, may be important for 
brain development as well as for maintenance of mental function 
later in life [75]. 
A role for cytokines in depression was first proposed by Smith 
[81] in the form of the ‘macrophage theory of depression’ and 
further studied. Building on the observation that patients with 
severe clinical depression have increased blood concentrations of 
inflammatory biomarkers, they proposed that depression is associated 
with an acute-phase response. According to his theory, the pro-
inflammatory cytokines that are responsible for this acute-phase 
reaction also cause various clinical aspects of depression, including 
hyperactivity of the hypothalamus–pituitary–adrenal axis, disturbed 
serotonin metabolism and near vegetative symptoms [82]. 
Vitamin D is now known to exert profound immune modulating 
effects by increasing the levels of anti-inflammatory cytokines such 
as IL-10, IL-4, IL-5 and transforming growth factor (TGF)-β, and by 
decreasing pro-inflammatory cytokines IL-1β, IL-2, IL-6, INF-γ, TNF-
α and IL-12 [83, 84]. The net result of these effects is a shift from a 
Th1 to a Th2 immunological phenotype, which is considered to be a 
less pro-inflammatory state [85].  
CONCLUSION 
The effect of Vitamin D deficiency in depression demonstrated in most 
meta-analysis is comparable with the effect of anti-depressant 
medication. However, future research should be performed to 
determine the role of vitamin D supplementation and dosage needed. 
At this time, modest sun exposure and vitamin D supplementation 
may be cost-effective with rare adverse effects in preventing the 
development of depression or attenuating the depressive symptoms. 
These findings may have important clinical and public health. 
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